Submitted by: Nymox Pharmaceutical Corporation
Posted: Mar 06, 2002 – 11:00 PM EST
Mar. 06 /CSRwire/ - Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today results from a highly successful study of its NicAlert(TM) product in children exposed to environmental tobacco smoke (ETS) ("second hand smoke").
NicAlert(TM) is Nymox's patented one-step test for smoking and tobacco product use. ETS is a major health problem associated with lung cancer, respiratory and cardiovascular disease. As a public health measure, NicAlert(TM) is useful for all children to detect important risk such as e.g. wheezing, coughing, asthma, allergy, and airway obstruction in association with repeated school absence, and increased physician visits and infections.
In the new study, NicAlert(TM) readings were compared in smokers, non-smokers, adults exposed to second hand smoke, and children with smoking or non-smoking adults in the household. The study found that NicAlert(TM) testing of urine could detect smoke exposure in all children with smokers in their homes and distinguish these individuals from those with a smoke-free environment.
Exposure to ETS may occur in the home, in the workplace, in social settings and in public places. NicAlert(TM) is a cost-effective easy-to-use test which can be applied to many situations such as athletic and school testing, insurance testing, workplace environment testing, research studies and smoking cessation. It is the only quantitative single step test available for ETS exposure.
Bonnie Brown, Nymox's Product Manager for NicAlert(TM), said, "We are very excited by these findings which open up a whole new important field of application for this highly innovative product. The one-step quantitative NicAlert(TM) test provides a lot more information than a simple yes or no."
Nymox has two products for smoking and tobacco product exposure. NicoMeter(TM) is used with urine and the new NicAlert(TM) is used for urine and saliva detection. These products have increasing utility for ETS exposure testing and testing individuals for tobacco product use. Nymox provides NicAlert(TM) at $8 per test. The Company is currently negotiating a number of new marketing initiatives for NicAlert(TM).
Nymox Pharmaceutical Corporation has facilities in Maywood, NJ and Montreal. Its stock is traded on NASDAQ with the symbol NYMX. More information is available at http://www.nymox.com.
This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
For more information, please contact: